Last reviewed · How we verify

NCT05969548

pBFS-guided cTBS at Different Doses for Aphasia After Stroke

Recruiting now NA Last updated 4 April 2025
What this trial tests

NA trial testing active 1200-pulse continuous Theta Burst Stimulation in Stroke in 60 participants. Currently enrolling.

Timeline
22 September 2023
Primary endpoint
22 September 2025
22 December 2025

Quick facts

Lead sponsorChangping Laboratory
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment60
Start date22 September 2023
Primary completion22 September 2025
Estimated completion22 December 2025
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Changping Laboratory

Who can join

Adults 35 to 75, any sex, with Stroke or Aphasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this trial is to evaluate the effectiveness and safeness of different doses of continuous Theta Burst Stimulation (cTBS) over the right Superior Frontal Gyrus (SFG), guided by personalized Brain Function Sector (pBFS) technology, on language function recovery in patients with post-stroke aphasia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Changping Laboratory trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05969548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing